New York, Feb 12, 2026, 14:56 ET — Session ongoing
- Thermo Fisher shares dropped roughly 4% in afternoon trading, continuing a decline that’s been ongoing for several days.
- The $3.8 billion debt package linked to the Clario acquisition is scheduled to close on Feb. 12.
- Thermo Fisher revealed a real-world data partnership with Datavant. At the same time, a filing showed an executive VP offloaded shares through a pre-arranged trading plan.
Thermo Fisher Scientific Inc shares dropped 4.3% to $504.53 during Thursday afternoon trading, marking a notable dip for a large-cap stock amid a volatile market session.
On Wednesday, the company announced a strategic partnership with Datavant to connect “real-world data” — like info from medical records and registries outside standard clinical trials — with clinical research. Karen Kaucic, Thermo Fisher’s chief medical officer for clinical research, emphasized that “data interoperability is critical to the next generation of evidence generation.” Arnaub Chatterjee, Datavant’s life sciences chief, highlighted that “reducing friction across the research lifecycle” was essential. Datavant
At the same time, a prospectus supplement submitted to the U.S. SEC revealed a $3.8 billion senior notes offering — corporate debt — with maturities stretching from 2031 to 2046 and coupons reaching as high as 5.546%. The filing states the proceeds will support Thermo Fisher’s upcoming Clario acquisition, valued at about $8.875 billion in cash at closing, plus deferred and contingent payments. The notes are expected to be issued “on or about” Feb. 12. SEC
A separate Form 4 filing revealed that executive vice president Gianluca Pettiti sold 400 shares on Feb. 9 at $541.20 each, reducing his direct holdings to roughly 20,752 shares. This sale was executed under a Rule 10b5-1 plan set up in September, which lets executives pre-schedule trades.
Thermo Fisher’s decline coincided with weakness elsewhere in the tools-and-diagnostics sector. Shares of Danaher, Waters, and Agilent also slipped. On the broader market front, the Nasdaq-100 ETF QQQ and the S&P 500 ETF SPY fell, while the healthcare ETF XLV barely moved.
Thermo Fisher’s stock fell for a second day straight ahead of Thursday, with trading volume heating up: roughly 3.3 million shares changed hands on Wednesday, surpassing the 50-day average noted by MarketWatch. The stock currently sits about 18% below its 52-week peak reached on Jan. 22, according to the same report.
Here’s why it’s important now: Thermo Fisher is doubling down on clinical research services and data-driven evidence. At the same time, it’s arranging new financing for a major acquisition. That mix inevitably sparks concerns about how well they’ll execute, the timing, and how much the financing will cost.
However, the best-case scenario isn’t set in stone. The SEC prospectus clearly states the financing doesn’t depend on the Clario deal closing. Plus, the acquisition still needs to clear usual conditions and regulatory approvals. Any delays could sour sentiment, even if the fundamentals remain solid.
Traders are now focused on the Feb. 12 settlement of the notes, watching closely for any follow-up filings that detail proceeds and their intended uses. They’re also looking for signals on when Clario will get approvals and how fast the Datavant deal starts impacting bookings at PPD.
